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Abstract: Inflammatory bowel disease (IBD) is defined as a chronic intestinal inflammation 
that results from host-microbial interactions in a genetically susceptible individual. IBDs are 
a group of autoimmune diseases that are characterized by inflammation of both the small and 
large intestine, in which elements of the digestive system are attacked by the body’s own immune 
system. This inflammatory condition encompasses two major forms, known as Crohn’s disease 
and ulcerative colitis. Patients affected by these diseases experience abdominal symptoms, 
including diarrhea, abdominal pain, bloody stools, and vomiting. Moreover, defects in intesti-
nal epithelial barrier function have been observed in a number of patients affected by IBD. In 
this review, we first describe the types and symptoms of IBD and investigate the role that the 
epithelial barrier plays in the pathophysiology of IBD as well as the major cytokines involved. 
We then discuss steps used to diagnose this disease and the treatment options available, and 
finally provide an overview of the recent research that aims to develop new therapies for such 
chronic disorders.
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Introduction
The inflammatory bowel diseases (IBDs) primarily include Crohn’s disease and ulcer-
ative colitis. Crohn’s disease is an IBD that causes inflammation anywhere along the 
lining of the digestive tract, while ulcerative colitis causes long-lasting inflammation 
in some part of the digestive tract (mainly the colon). The exact etiology of IBD is 
not well known. There are several factors that have been postulated to have an effect 
on the development of this group of diseases, which include but are not limited to 
bacterial contamination, a change in the immune system, and genetic variations. For 
instance, a mutation in the NOD2 gene is associated with an increase susceptibility 
to IBD via production of proinflammatory cytokines.1 While genetic predisposition 
plays a key role in immune-mediated diseases, the major influence appears to be 
due to environmental factors.2 Indeed, current research suggests that autoimmune 
diseases are most prevalent in highly industrialized nations but rare in less developed 
countries.3  Moreover, studies have shown that increased consumption of milk protein, 
animal protein, and polyunsaturated fatty acids can increase the risk for IBD,4 and that 
consumption of tobacco increases the risk of Crohn’s disease.5
The major subtypes of IBD, including Crohn’s disease and ulcerative colitis, have a 
high prevalence rate in the world, with North America noting the highest frequency of 
people suffering with Crohn’s disease. In addition, statistics show that an estimated 129,000 
people live with the disease in Canada. Although the onset of the  disease usually occurs 





during adulthood, children are increasingly being diagnosed 
with IBD. Treating IBD often involves use of medications that 
can diminish the symptoms and decrease the inflammation in 
the colon lining. A group of anti-inflammatory drugs including 
5-aminosalicylic acid is commonly used to treat IBD.6 Other 
drugs such as infliximab are also indicated in patients who have 
failed conventional therapy and are hospitalized with severe 
IBD. Infliximab is a chimeric monoclonal antibody against 
tumor necrosis factor alpha (TNF-α), a cytokine involved in 
intestinal inflammation. Several other immunomodulatory 
drugs, such as thalidomide, can also be used to treat a patient 
with severe IBD. Formerly used as a sedative and hypnotic, 
this synthetic drug has been shown to significantly reduce the 
inflammation associated with IBD.7 However, under certain 
circumstances, when medical therapy fails, surgery may be 
considered. This operation is known as colectomy and involves 
removal of the large intestine. While ulcerative colitis is cured 
upon removal of the colon, Crohn’s disease unfortunately can 
still recur after surgery.
While medication is commonly used to treat IBD, most 
pharmaceutical compounds have side effects such as head-
ache, diarrhea, and nausea, which can reduce patient com-
pliance and result in worsening of the condition. Therefore, 
appropriate delivery systems must be developed in order 
to overcome the limitations and issues associated with the 
currently available treatments for IBD. Artificial cell micro-
encapsulation is a promising tool in scientific research that 
allows for targeted delivery of pharmaceutical compounds in a 
time-dependent fashion.7 Current research aims at developing 
such a platform in order to deliver anti-inflammatory drugs to 
the areas of the gastrointestinal tract most affected by IBD.
Types and symptoms of IBD
Although Crohn’s disease and ulcerative colitis share similar 
characteristics, they differ in terms of the location and nature 
of the inflammatory changes. The distinction between these 
two diseases is that in Crohn’s disease inflammation can 
affect any part of the gastrointestinal tract, while ulcerative 
colitis is characterized by inflammation localized to the large 
intestine. The prevalence of Crohn’s disease is relatively high 
in highly industrialized countries. Its incidence is five in 
100,000 people and its prevalence is estimated to be 30–50 
of 100,000 people in western countries.8 At the microscopic 
level, Crohn’s disease affects the entire bowel wall, while 
ulcerative colitis is restricted to the epithelial lining of 
the gut. Since the two diseases share similar symptoms, the 
diagnosis of one form of IBD over the other is often very 
difficult. As previously mentioned, medical treatment of IBD 
is strongly dependent on the use of immunosuppressive drugs 
and anti-inflammatory compounds.9 Although immunosup-
pressive therapies such as azathioprine, mercaptopurine, and 
methotrexate are currently available, achieving remission 
of IBD in patients remains a clinical challenge.10 This class 
of therapeutics is very efficient in reducing the extent of 
inflammation, but it presents a wide range of side effects. For 
instance, administration of such pharmaceutical compounds 
can cause fluid retention, insomnia, weight gain, drowsiness, 
hypertension, constipation, and vomiting. Therefore, in the 
ongoing research for additional therapeutics, several studies 
have focused on the development of new formulations to treat 
IBD with minimal side effects, improved patient compliance, 
and therefore better clinical outcomes.
Symptoms tend to vary depending on the type of IBD. 
A comparison of the key features in Crohn’s disease and 
ulcerative colitis is shown in Table 1. Patients affected by 
ulcerative colitis tend to experience pain in the lower left part 
of the abdomen as well as diarrhea. As a result, they may 
experience weight loss and blood on rectal examination. In 
contrast, patients with Crohn’s disease experience pain in 
the lower right abdomen, and bleeding from the rectum is 
less frequent than in ulcerative colitis. The most common 
complication of Crohn’s disease is blockage of the intestine 
due to swelling, which results in thickening of the bowel wall. 
Moreover, people affected by this disease often encounter 
problems related to malnutrition or the presence of nutritional 
deficiencies, as a result of poor absorption. Several studies 
have found an increased risk of death in people affected by 
Crohn’s disease. Analyses of colorectal and small bowel 
cancer studies have found that people with Crohn’s disease 
also suffered with comorbidities such as colorectal cancer, 
cardiovascular disease, and respiratory disease.11,12 Similarly, 
there have been several studies of the mortality associated 
with ulcerative colitis. However, no significant difference in 
Table 1 Comparison of key features in Crohn’s disease and 
ulcerative colitis
Key features Crohn’s disease Ulcerative colitis
Location  
  Upper parts of GIT  













Signs and symptoms Pain in the lower  
right abdomen,  
swelling, thickening  
of the bowel wall
Pain in the lower left 
abdomen, diarrhea, 
weight loss, rectal 
bleeding
Abbreviation: GIT, gastrointestinal tract.





mortality risk was reported with ulcerative colitis. Indeed, it 
was shown that people with ulcerative colitis have the same 
mortality risk as the general population.13,14
Intestinal barrier in IBD
Understanding the properties and characteristics of the gas-
trointestinal tract can aid in the identification of the biomo-
lecular mechanisms involved in IBD, and can foster new ideas 
for the development of therapies for such chronic disorders. 
A variety of defense mechanisms are aimed at minimizing 
infections caused by IBD, and include physical barriers such 
as tightly adherent epithelial cells, antimicrobial peptides 
secreted by intestinal epithelial cells, and complex mucosal 
innate and adaptive immune arms aimed at eliminating 
invasive infections.15 The gastrointestinal tract consists of 
four separate layers that reflect specialization in functional 
anatomy, ie, the mucosa, submucosa, muscularis externa, and 
adventitia.16 The mucosa is the inner layer of the gastrointes-
tinal tract and plays a very significant role in the digestion of 
food. It forms a barrier between the internal organs and the 
lumen of the gastrointestinal tract. This layer mainly consists 
of epithelial cells that are connected by tight junctions and 
play an important role in allowing the transport of nutrients 
across the epithelium, while preventing the passage of mol-
ecules that might be harmful to the host.17 These epithelial 
linings also contain goblet cells and endocrine cells.18 The 
sole function of goblet cells is to secrete mucin, which forms 
mucus when dissolved in water. Endocrine cells, commonly 
found in the epithelial wall, secrete a type of hormone that 
plays a crucial role in the regulation of digestive processes. 
External microorganisms that are able to breach the epithelial 
wall have unrestricted access to the circulation, which is 
one of the main causes of gastrointestinal disease. Indeed, 
murine and human studies have demonstrated that IBDs, 
such as Crohn’s disease, are characterized by a defect in the 
epithelial barrier and altered mucus production, leading to 
an increase in intestinal permeability and toxins adherence 
in the intestinal cells.15,19
As illustrated in Figure 1, Crohn’s disease is characterized 
by a defect in the integrity of the epithelial barrier, resulting 
in translocation of microbial antigens and other external 
agents.20 Several studies have demonstrated increased adher-
ent bacteria in patients with Crohn’s disease.15 Exposure of 
the mucosal immune system to external luminal contents 
will significantly increase the production of proinflammatory 
cytokines and favor a differentiation of T-cells to T-helper 
(Th)1-type effector cells, which triggers the release of proin-
flammatory cytokines.
Role of cytokines in IBD
Th cells are a subclass of lymphocytes that play a key role in 
mediating the immune response. They are involved in activat-
ing other immune cells and in determining the specificity of 



















Figure 1 Triggering of immune response in Crohn’s disease. The main molecules involved are TGF-β, Tregs, TLR, DCs, Th cells, and TL1A.
Note: Reprinted from Cobrin GM, Abreu MT. Defects in mucosal immunity leading to Crohn’s disease. Immunol Rev. 2005;206:277–295.20 Copyright © 2005, John wiley 
and Sons. 
Abbreviations: DCs, dendritic cells; TGF-β, transforming growth factor beta; Tregs, regulatory T-cells; TLR, Toll-like receptors; Th, T-helper; TL1A, TNF-like ligand 1A; 
IL, interleukin; TNF-α, tumor necrosis factor alpha; IFN-γ, interferon gamma.

















Figure 2 Factors determining T-lymphocyte differentiation in inflammatory bowel 
disease.
Abbreviations: Th, T-helper; IL, interleukin; TNF-α, tumor necrosis factor alpha; 
IFN-γ, interferon gamma; NK, natural killer.
Upon proliferation, a Th cell differentiates into Th1 cells, 
Th2 cells, or other Th lineages. As shown in Figure 2, Th1 
cells mediate the production of proinflammatory cytokines, 
such as interferon gamma (IFN-γ), TNF-α, and interleukin 
(IL)-2, which are part of cell-mediated immunity. In contrast, 
Th2 cells lead to production of anti-inflammatory cytokines, 
including IL-4, IL-5, IL-6, and IL-10, which constitute the 
humoral immune response. There is a mutual interaction 
between Th1 and Th2 lymphocytes; Th1 cytokines drive 
Th1 cell production and inhibit Th2 cells. Conversely, Th2 
cytokines drives Th2 cell production and inhibit Th1 cells. In 
a normal situation, there is a balance between the amounts of 
Th2 and Th1 cells.11 The development of immune-mediated 
disorders like Crohn’s disease is strongly related to a polar-
ized type 1 immune response causing chronic inflammation 
of the gut.22
Administration of anti-inflammatory drugs protects 
the individual from Crohn’s disease by attenuating the 
Th1 response and enhancing Th2-mediated activity. This 
immune modulation causes a switch of the immune 
response from a Th1-mediated to a Th2-mediated 
 activity, thus significantly reducing the extent of bowel 
inflammation.23,24
TNF-α is a proinflammatory cytokine that plays a 
major role in the inflammation caused by IBD. Levels of 
TNF-α are significantly increased in response to intestinal 
inflammation. Indeed, clinical studies have demonstrated 
that serum TNF-α levels are elevated in patients with IBD.25 
Elevated TNF-α levels can be confirmed in a patient by 
viewing both  histologically normal mucosa and inflamed 
mucosa. An increase in TNF-α induces cell proliferation 
and differentiation, and leads to upregulation of adhesion 
molecules on endothelial cells.26 TNF-α is also involved 
in apoptosis via recruitment and autoproteolytic activation 
of caspases. Therefore, the aim of the current research is to 
design an anti-TNF-α therapy that can dampen the inflam-
mation related to IBD in patients.
Diagnosis of IBD
Several techniques and medical tests are available to aid 
the physician in the diagnosis of IBD. Such a technique is 
available for Crohn’s disease, and utilizes capsule endoscopy 
to diagnose a patient effectively. Since capsule endoscopy 
requires a clean colon prior to use, the patient should take 
an appropriate drinking formulation that has a good safety 
profile. The capsule, which is the size of a pill, can take 
pictures of the inner layer of the gastrointestinal tract when 
orally ingested. These endoscopic images can localize 
small erosions and ulcerations that may be evident along 
the gastrointestinal tract and help physicians identify the 
location of inflammation.27 An alternative to endoscopy is 
radiology tests that can aid in the diagnosis of the disease. 
For example, a barium follow-through procedure is a use-
ful medical imaging technique for Crohn’s disease when 
only the small intestine is involved.28 In this technique, 
the patient drinks a solution containing barium sulfate that 
appears white on X-ray and highlights the internal lining of 
the bowel. Another diagnostic tool for IBD involves testing 
of blood samples from patients.  Laboratory blood tests may 
show elevated sedimentation rates and white cell counts, 
both of which are associated with intestinal inflammation. 
Complete blood counts from patients with IBD may reveal 
anemia caused by vitamin B12 deficiency and autoimmune 
hemolysis.29 Moreover, increasing amounts and levels of 
serological markers may be useful in the diagnosis of IBD 
and also for differentiation between Crohn’s disease and 
ulcerative colitis.30,31
X-ray computed tomography and magnetic resonance 
imaging scans are also commonly used to look for intra-
abdominal complications of IBD, such as small bowel 
obstruction, abscesses, or fistulae.32 Computed tomography 





is a technique that utilizes multidetector scanners with high 
spatial and temporal resolution in order to permit visualiza-
tion of the small bowel wall, mucosa, and lumen.33 It can 
delineate the extent and severity of inflammation of the 
bowel wall, and can also detect submucosal fat deposition, 
sacculations, and fibrofatty proliferation. The presence 
of intramural fat indicates past or chronic inflammation, 
while sacculations result from the chronic inflammatory 
process, leading to fibrosis and asymmetric shortening of 
the mesenteric border of the wall.34 Magnetic resonance 
imaging has undergone the same technical advances as 
seen with computed tomography. Its spatial and temporal 
resolution of images allows evaluation of bowel wall contrast 
enhancement, wall thickening, and edema, which is useful 
for assessment of IBD activity.33
Biopsies of the colon can be taken to confirm the 
 diagnosis. This technique is very effective in diagnosing 
the disease and in differentiating the type of inflammation. 
Certain features of the pathology seem to be characteris-
tic of the inflammation associated with Crohn’s disease. 
A transmural pattern of inflammation is often seen in this 
disease, meaning that the inflammation may span the entire 
depth of the intestinal wall. Under the microscope, biopsy 
of the affected colon may show mucosal damage, character-
ized by focal infiltration of leukocytes into the epithelium.7 
Granulomas, ie, aggregates of immune cells known as mac-
rophages, are also found (Figure 3) and are most specific 
for Crohn’s disease.35
The pathology in ulcerative colitis typically involves 
hemorrhage or inflammatory cells in the lamina propria 
Figure 3 Granulomas in Crohn’s disease. Hematoxylin and eosin staining on the 
stomach shows gastric mucosal biopsy containing two characteristic granulomas 
(10×).
Table 2 Histologic and endoscopic findings in Crohn’s disease 
versus ulcerative colitis





presence of  
granulomas






lesions, strictures,  
linear ulcerations
Continuous lesions, presence 
of crypts, formation of residual 
mucosal tissue
and distortion of crypt architecture. The latter is the result 
of crypt abscess, during which the epithelium of the crypt 
breaks down and polymorphonuclear cells aggregate in the 
lumen.35
Other differences between Crohn’s disease and ulcerative 
colitis can be observed on histology, as shown in Table 2. For 
instance, significant thickening of the mucosa and to a lesser 
extent in the submucosa can be observed in patients with 
active ulcerative colitis. However, these structures appear to 
be quite normal in active Crohn’s disease.36
Major treatments and limitations
Medication used for IBD
There is no known medical or surgical cure for IBD. 
 Treatment of the disease involves use of anti-inflammatory 
drugs that can significantly reduce the symptoms of the 
disease and help maintain its remission. Medications used 
to treat the symptoms of IBD include anti-inflammatory 
drugs, such as 5-aminosalicylic acid,37 and immunomodu-
lators, such as azathioprine, mercaptopurine, methotrexate, 
infliximab, adalimumab, certolizumab, and natalizumab. 
These compounds regulate the immune system by effi-
ciently triggering a Th2-mediated response that dampens 
Th1-mediated inflammation. This results in production 
of anti-inflammatory cytokines such as IL-4, IL-5, IL-6, 
and IL-10 that inhibit production of proinflammatory 
cytokines. Oral delivery of such compounds has been 
shown to be successful against intestinal inflammation,8 
but has several limitations when administered in high 
doses. These limitations are mainly due to the fact that 
most of the administered drug is delivered to nonspecific 
cells in the body, resulting in either infusion reactions or 
undesirable side effects.
Monoclonal antibodies
Anti-TNF-α antibodies are frequently used to treat IBD 
because they are able to efficiently reduce the amount of 





TNF-α in the body. Recent studies suggest that infliximab, 
a monoclonal antibody, is a potential treatment for Crohn’s 
disease because it neutralizes TNF-α by preventing it from 
interacting with its receptor.38,39 The complementarities 
between the TNF-α molecule and the variable region of inf-
liximab make this antibody a promising treatment for Crohn’s 
disease and other autoimmune disorders. However, there are 
major limitations associated with infliximab in that patients 
can develop tuberculosis soon after the initiation of treatment, 
which is often due to TNF-α neutralization.40 Delayed hyper-
sensitivity reactions are also frequently observed following 
administration of infliximab. Moreover, infliximab cannot be 
administered orally, since the digestive system would destroy 
it, and needs to be administered via an intravenous infusion 
at 6–8-week intervals. Other antibodies, such as adalimumab 
and certolizumab, have also shown significant positive results 
in the treatment of IBD.41
Thalidomide
Thalidomide was first manufactured by a German pharma-
ceutical company and was found to be an effective sedative 
and tranquilizer for insomnia, colds, and headaches. It was 
introduced onto the market in 1957 in several countries 
as an immunomodulatory agent to treat diseases such 
as multiple myeloma. However, it was withdrawn from the 
market in 1961 after it was found to be associated with 
severe birth defects when administered during pregnancy,42 
but was then approved in July 1988 by the US Food and 
Drug  Administration. The drug can now be administered to 
patients in the USA under strict guidelines. Thalidomide is 
involved in the pathophysiology of Crohn’s disease since it 
suppresses all the major cytokines that participate in intesti-
nal  inflammation. Likewise, thalidomide destabilizes TNF-α 
messenger RNA, leading to a significant decrease in the 
amount of TNF-α, a proinflammatory cytokine responsible 
for the inflammation of Crohn’s disease.43 It also stimulates 
the production of cytotoxic T-cells, resulting in an increase 
in the number of T-lymphocytes.44 Although thalidomide 
is beneficial in dampening the production of proinflam-
matory cytokines, it has several limitations, including 
drowsiness, hypertension, skin rash, edema, and neutropenia. 
 Appropriate drug delivery systems must be developed in 
order to  successfully release thalidomide in the areas of the 
gastrointestinal tract most affected by the disease.
Drug-loaded microcapsules
Artificial cell microencapsulation is a promising tool in 
scientific research that allows the delivery of  pharmaceutical 
compounds to specif ic tissues in the body in a time-
 dependent manner.45 Artificial cell microencapsulation 
involves preparation of an artificial structure using dif-
ferent types of polymers and proteins. It can contain a 
variety of molecular structures, including DNA, drugs, 
enzymes, antibodies, bacteria cells, mammalian cells, and 
other microorganisms.46 Several publications suggest the 
use of alginate-polylysine-alginate (APA) microcapsules 
as an efficient platform for the delivery of pharmaceutical 
compounds.7,45 APA microcapsules are formed by ionic 
interactions between negatively charged alginate mol-
ecules and positively charged calcium ions. Preliminary 
data suggest that APA capsules remain intact in the low 
pH environment normally encountered in the stomach.47 
In the small intestine, the capsule degrades at a slow rate 
and releases its content in a time-dependent  manner. The 
in vivo biocompatibility of artificial microcapsules has 
been demonstrated, and they have shown no signs of clini-
cal toxicity.48 A recent study has evaluated the potential of 
artificial cell microencapsulation of thalidomide in the 
remission of Crohn’s disease using a well established model 
of 2,4,6-trinitrobenzene sulfonic acid-induced inflamma-
tion in mice.7 It was shown that this artificial structure 
could release the drug into the intestines and decrease the 
degree of intestinal inflammation by lowering the level of 
proinflammatory cytokines, while at the same time limiting 
the side effects associated with thalidomide.
Conclusion
Although there is no cure for IBD, we now have sufficient 
evidence that several pharmaceutical compounds are able 
to dampen the intestinal inflammation. This review provides 
an overview of the experimental studies done using mono-
clonal antibodies and anti-inflammatory drugs. Most of the 
results reported in the papers show that anti-inflammatory 
compounds can inhibit the proliferation of cytokines such 
as TNF-α and IFN-γ, but unfortunately have potential side 
effects, including vomiting, diarrhea, and nausea. Use of 
appropriate drug delivery systems such as artificial cell 
microencapsulation has shown promising results with 
regard to limiting these side effects as well as enhancing 
the inhibition of intestinal inflammation. However, many 
questions still remain. Existing studies are encouraging, 
but most are  inconclusive. More research, both in animal 
models and in clinical trials, is necessary to validate the 
newer and potentially more effective treatment options for 
the eventual commercialization of new IBD therapies. The 
coming years will be crucial. The information obtained 





from ongoing and future clinical trials will help us better 
understand the pathophysiology of intestinal inflammation in 
IBD and may have a significant impact on treating patients 
with the disease.
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